Trial Profile
Double-blind, placebo-controlled, multiple-dose study of oral administration of the NK3 receptor antagonist ESN 364 in healthy pre-menopausal women.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2015
Price :
$35
*
At a glance
- Drugs Fezolinetant (Primary)
- Indications Sex hormone disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Euroscreen
- 11 Aug 2015 New trial record